Ego Pharmaceuticals has once again been named on the Top 500 Private Companies list, released last week by the Australian Financial Review. In a volatile environment, impacted significantly by the COVID-19 pandemic and subsequent restrictions, Ego is proud to have retained its place on the list at number 309.
The list, published annually, considers company revenue over the latest 12-month accounting period as well as the number of staff employed.
Ego Pharmaceuticals was founded in Melbourne by husband and wife Gerald and Rae Oppenheim in 1953, and now employs over 600 staff across 15 nations.
The organisation remains Australian family owned and operated, with all products still being manufactured in Victoria.
Ego is committed to investing in the future growth of high-technology manufacturing with the benefit of providing good jobs and strong economic growth for Australia and in all nations in which the company operates.
Ego is in the final stages of a $25 million dollar ‘Green Core’ upgrade project at its manufacturing facility in Braeside, which is due for completion in June 2022. This investment will improve Ego’s operating capacity to enable future projects and expansion, and will also reduce the company’s environmental impact.
